Drugs acting on homeostasis: challenging cancer cell adaptation

References

• Bougarne N, Paumelle R, Caron S, et al. PPARalpha blocks glucocorticoid receptor alpha-mediated transactivation but cooperates with the activated glucocorticoid receptor alpha for transrepression on NF-kappaB. Proc. Natl Acad Sci USA 2009;106(18):7397-402
   PubMed Web of Science ®Google Scholar
• Epple LM, Dodd RD, Merz AL, et al. Induction of the unfolded protein response drives enhanced metabolism and chemoresistance in glioma cells. PLoS ONE 2013;8(8):e73267
   PubMed Web of Science ®Google Scholar
• Vlahopoulos SA, Cen O, Hengen N, et al. Dynamic aberrant NF-κB spurs tumorigenesis: A new model encompassing the microenvironment. Cytokine Growth Factor Rev 2015;26(4):389-403
   PubMed Web of Science ®Google Scholar
• Pazienza V, Vinciguerra M, Mazzoccoli G. PPARs Signaling and Cancer in the Gastrointestinal System. PPAR Res 2012;2012:560846
   PubMedGoogle Scholar
• Li B, Simon MC. Molecular Pathways: Targeting MYC-induced metabolic reprogramming and oncogenic stress in cancer. Clin Cancer Res 2013;19(21):5835-41
   PubMed Web of Science ®Google Scholar
• Kono Y, Kawakami S, Higuchi Y, et al. In vitro evaluation of inhibitory effect of nuclear factor-kappaB activity by small interfering RNA on pro-tumor characteristics of M2-like macrophages. Biol Pharm Bull 2014;37(1):137-44
   PubMed Web of Science ®Google Scholar
• Copland JA, Sheffield-Moore M, Koldzic-Zivanovic N, et al. Sex steroid receptors in skeletal differentiation and epithelial neoplasia: is tissue-specific intervention possible? BioEssays 2009;31(6):629-41
   PubMed Web of Science ®Google Scholar
• Fissolo N, Kraus M, Reich M, et al. Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation. Eur J Immunol 2008;38(9):2401-11
   PubMed Web of Science ®Google Scholar
• Wu S, Wang X, Chen J, Chen Y. Autophagy of cancer stem cells is involved with chemoresistance of colon cancer cells. Biochem Biophys Res Commun 2013;434(4):898-903
   PubMed Web of Science ®Google Scholar
• Wu W, Zhao S. Metabolic changes in cancer: beyond the Warburg effect. Acta Biochim Biophys Sin 2013;45(1):18-26
   Google Scholar
• Halvey PJ, Wang X, Wang J, et al. Proteogenomic analysis reveals unanticipated adaptations of colorectal tumor cells to deficiencies in DNA mismatch repair. Cancer Res 2014;74(1):387-97
   PubMed Web of Science ®Google Scholar
• Nyati MK, Feng FY, Kanade VD, Nayak R. Chloroquine treatment increases detection of 5-fluorouracil-induced apoptosis index in vivo. Mol Imaging 2006;5(3):148-52
   PubMed Web of Science ®Google Scholar
• Yadunandam AK, Yoon J-S, Seong Y-A, et al. Prospective impact of 5-FU in the induction of endoplasmic reticulum stress, modulation of GRP78 expression and autophagy in Sk-Hep1 cells. Int J Oncol 2012;41(3):1036-42
   PubMed Web of Science ®Google Scholar
• Ullman E, Pan J-A, Zong W-X. Squamous cell carcinoma antigen 1 promotes caspase-8-mediated apoptosis in response to endoplasmic reticulum stress while inhibiting necrosis induced by lysosomal injury. Mol Cell Biol 2011;31(14):2902-19
   PubMed Web of Science ®Google Scholar
• Abraham P, Isaac B. Ultrastructural changes in the rat kidney after single dose of cyclophosphamide–possible roles for peroxisome proliferation and lysosomal dysfunction in cyclophosphamide-induced renal damage. Hum Exp Toxicol 2011;30(12):1924-30
   PubMed Web of Science ®Google Scholar
• Anton E. Delayed toxicity of cyclophosphamide in normal mice. Br J Exp Pathol 1987;68(2):237-49
   PubMed Web of Science ®Google Scholar
• Chou Y-W, Zhang L, Muniyan S, et al. Androgens upregulate Cdc25C protein by inhibiting its proteasomal and lysosomal degradation pathways. PLoS One 2013;8(4):e61934
   PubMed Web of Science ®Google Scholar
• Salerni BL, Bates DJ, Albershardt TC, et al. Vinblastine induces acute, cell cycle phase-independent apoptosis in some leukemias and lymphomas and can induce acute apoptosis in others when Mcl-1 is suppressed. Mol Cancer Ther 2010;9(4):791-802
   PubMed Web of Science ®Google Scholar
• Sánchez-Pérez T, Ortiz-Ferrón G, López-Rivas A. Mitotic arrest and JNK-induced proteasomal degradation of FLIP and Mcl-1 are key events in the sensitization of breast tumor cells to TRAIL by antimicrotubule agents. Cell Death Differ 2010;17(5):883-94
   PubMed Web of Science ®Google Scholar
• Chang L, Kamata H, Solinas G, et al. The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell 2006;124(3):601-13
   PubMed Web of Science ®Google Scholar
• Ashley JD, Stefanick JF, Schroeder VA, et al. Liposomal Carfilzomib Nanoparticles Effectively Target Multiple Myeloma Cells and Demonstrate Enhanced Efficacy In Vivo. J Control Release Off 2014
   PubMed Web of Science ®Google Scholar
• Pang B, Qiao X, Janssen L, et al. Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nat Commun 2013;4:1908
   PubMed Web of Science ®Google Scholar
• Govender J, Loos B, Marais E, Engelbrecht A-M. Mitochondrial catastrophe during doxorubicin-induced cardiotoxicity: a review of the protective role of melatonin. J Pineal Res 2014;57(4):367-80
   PubMed Web of Science ®Google Scholar
• Chen J-Y, Hu R-Y, Chou H-C. Quercetin-induced cardioprotection against doxorubicin cytotoxicity. J Biomed Sci 2013;20:95
   PubMed Web of Science ®Google Scholar
• Lin S-T, Lo Y-W, Chang S-J, et al. Redox-proteomic analysis of doxorubicin resistance-induced altered thiol activity in uterine carcinoma. J Pharm Biomed Anal 2013;78-79:1-8
   PubMed Web of Science ®Google Scholar
• Davis AL, Cabello CM, Qiao S, et al. Phenotypic identification of the redox dye methylene blue as an antagonist of heat shock response gene expression in metastatic melanoma cells. Int J Mol Sci 2013;14(2):4185-202
   PubMed Web of Science ®Google Scholar
• Zhang Y, Dayalan Naidu S, Samarasinghe K, et al. Sulphoxythiocarbamates modify cysteine residues in HSP90 causing degradation of client proteins and inhibition of cancer cell proliferation. Br J Cancer 2014;110(1):71-82
   PubMed Web of Science ®Google Scholar
• Paleos CM, Sideratou Z, Theodossiou TA, Tsiourvas D. Carboxylated Hydroxyethyl Starch: A novel Polysaccharide for the Delivery of Doxorubicin. Chem Biol Drug Des 2014
   PubMed Web of Science ®Google Scholar
• Martinez-Outschoorn U, Sotgia F, Lisanti MP. Tumor microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function. Semin Oncol 2014;41(2):195-216
   PubMed Web of Science ®Google Scholar
• Bluemlein K, Glückmann M, Grüning N-M, et al. Pyruvate kinase is a dosage-dependent regulator of cellular amino acid homeostasis. Oncotarget 2012;3(11):1356-69
   PubMedGoogle Scholar
• Wang F, Yang Y. Inhibition of PKM2 sensitizes triple-negative breast cancer cells to doxorubicin. Biochem Biophys Res Commun 2014;454(3):465-70
   PubMed Web of Science ®Google Scholar
• Isaac ST, Tan TC, Polly P. Endoplasmic Reticulum Stress, Calcium Dysregulation and Altered Protein Translation: Intersection of Processes that Contribute to Cancer Cachexia Induced Skeletal Muscle Wasting. Curr Drug Targets 2015
   PubMedGoogle Scholar
• Hochster HS, Grothey A, Hart L, et al. Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT. Ann Oncol 2014;25(6):1172-8
   PubMed Web of Science ®Google Scholar
• Monteith GR, Davis FM, Roberts-Thomson SJ. Calcium channels and pumps in cancer: changes and consequences. J Biol Chem 2012;287(38):31666-73
   PubMed Web of Science ®Google Scholar
• Taylor JT, Zeng X-B, Pottle JE, et al. Calcium signaling and T-type calcium channels in cancer cell cycling. World J Gastroenterol WJG 2008;14(32):4984-91
   PubMed Web of Science ®Google Scholar
• Santoni G, Santoni M, Nabissi M. Functional role of T-type calcium channels in tumour growth and progression: prospective in cancer therapy. Br J Pharmacol 2012;166(4):1244-6
   PubMed Web of Science ®Google Scholar
• Shapovalov G, Skryma R, Prevarskaya N. Calcium channels and prostate cancer. Recent Patents Anticancer Drug Discov 2013;8(1):18-26
   PubMed Web of Science ®Google Scholar
• Kania E, Pająk B, Orzechowski A. Calcium Homeostasis and ER Stress in Control of Autophagy in Cancer Cells. BioMed Res. Int 2015;2015:352794
   Google Scholar
• Macià A, Herreros J, Martí RM, Cantí C. Calcium channel expression and applicability as targeted therapies in melanoma. BioMed Res Int 2015;587135
   Google Scholar
• Ekström EJ, Bergenfelz C, von Bülow V, et al. WNT5A induces release of exosomes containing pro-angiogenic and immunosuppressive factors from malignant melanoma cells. Mol Cancer 2014;13:88
   PubMed Web of Science ®Google Scholar
• Robert V, Triffaux E, Savignac M, Pelletier L. Singularities of calcium signaling in effector T-lymphocytes. Biochim Biophys Acta 2013;1833(7):1595-602
   PubMed Web of Science ®Google Scholar
• Bellodi C, Lidonnici MR, Hamilton A, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 2009;119(5):1109-23
   PubMed Web of Science ®Google Scholar
• Crowley LC, O’Donovan TR, Nyhan MJ, McKenna SL. Pharmacological agents with inherent anti-autophagic activity improve the cytotoxicity of imatinib. Oncol Rep 2013;29(6):2261-8
   PubMed Web of Science ®Google Scholar
• Martinez Marignac VL, Smith S, Toban N, et al. Resistance to Dasatinib in primary chronic lymphocytic leukemia lymphocytes involves AMPK-mediated energetic re-programming. Oncotarget 2013;4(12):2550-66
   PubMedGoogle Scholar
• Lambrou GI, Papadimitriou L, Chrousos GP, Vlahopoulos SA. Glucocorticoid and proteasome inhibitor impact on the leukemic lymphoblast: multiple, diverse signals converging on a few key downstream regulators. Mol Cell Endocrinol 2012;351(2):142-51
   PubMed Web of Science ®Google Scholar
• Tricot G. New insights into role of microenvironment in multiple myeloma. Lancet 2000;355(9200):248-50
   PubMed Web of Science ®Google Scholar
• Adams J. Proteasome inhibition: a novel approach to cancer therapy. Trends Mol. Med 2002;8(Suppl 4):S49-54
   Web of Science ®Google Scholar
• Vlahopoulos S, Critselis E, Voutsas IF, et al. New use for old drugs? Prospective targets of chloroquines in cancer therapy. Curr Drug Targets 2014;15(9):843-51
   PubMed Web of Science ®Google Scholar
• Moriya S, Che X-F, Komatsu S, et al. Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells. Int J Oncol 2013;42(5):1541-50
   PubMed Web of Science ®Google Scholar
• Appelqvist H, Johansson A-C, Linderoth E, et al. Lysosome-mediated apoptosis is associated with cathepsin D-specific processing of bid at Phe24, Trp48, and Phe183. Ann Clin Lab Sci 2012;42(3):231-42
   PubMed Web of Science ®Google Scholar
• Werneburg NW, Bronk SF, Guicciardi ME, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein-induced lysosomal translocation of proapoptotic effectors is mediated by phosphofurin acidic cluster sorting protein-2 (PACS-2). J Biol Chem 2012;287(29):24427-37
   PubMed Web of Science ®Google Scholar
• Märten A, Zeiss N, Serba S, et al. Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma. Mol Cancer Ther 2008;7(11):3624-31
   PubMed Web of Science ®Google Scholar
• Zhu H, Wang D, Liu Y, et al. Role of the Hypoxia-inducible factor-1 alpha induced autophagy in the conversion of non-stem pancreatic cancer cells into CD133+ pancreatic cancer stem-like cells. Cancer Cell Int 2013;13(1):119
   PubMed Web of Science ®Google Scholar
• Baracca A, Sgarbi G, Padula A, Solaini G. Glucose plays a main role in human fibroblasts adaptation to hypoxia. Int J Biochem Cell Biol 2013;45(7):1356-65
   PubMed Web of Science ®Google Scholar
• Sionov RV. MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies. ISRN Hematol 2013;2013:348212
   Google Scholar
• Jiang N, Koh GS, Lim JY, et al. BIM is a prognostic biomarker for early prednisolone response in pediatric acute lymphoblastic leukemia. Exp Hematol 2011;39(3):321-9, 329.e1–3
   PubMed Web of Science ®Google Scholar
• Chen S, Zhang Y, Zhou L, et al. A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis. Blood 2014;124(17):2687-97
   PubMed Web of Science ®Google Scholar
• Haissaguerre M, Saucisse N, Cota D. Influence of mTOR in energy and metabolic homeostasis. Mol Cell Endocrinol 2014
   Google Scholar
• Guertin DA, Stevens DM, Saitoh M, et al. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 2009;15(2):148-59
   PubMed Web of Science ®Google Scholar
• Jordan NJ, Dutkowski CM, Barrow D, et al. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro. Breast Cancer Res BCR 2014;16(1):R12
   PubMed Web of Science ®Google Scholar
• Akhavan D, Cloughesy TF, Mischel PS. mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro-Oncol 2010;12(8):882-9
   PubMed Web of Science ®Google Scholar
• Zhang J, Grindley JC, Yin T, et al. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 2006;441(7092):518-22
   PubMed Web of Science ®Google Scholar
• Signer RAJ, Magee JA, Salic A, Morrison SJ. Haematopoietic stem cells require a highly regulated protein synthesis rate. Nature 2014;509(7498):49-54
   PubMed Web of Science ®Google Scholar
• Layani-Bazar A, Skornick I, Berrebi A, et al. Redox modulation of adjacent thiols in VLA-4 by AS101 converts myeloid leukemia cells from a drug-resistant to drug-sensitive state. Cancer Res 2014;74(11):3092-103
   PubMed Web of Science ®Google Scholar
• Malara N, Focà D, Casadonte F, et al. Simultaneous inhibition of the constitutively activated nuclear factor kappaB and of the interleukin-6 pathways is necessary and sufficient to completely overcome apoptosis resistance of human U266 myeloma cells. Cell Cycle Georget Tex 2008;7(20):3235-45
   PubMed Web of Science ®Google Scholar
• Markovina S, Callander NS, O’Connor SL, et al. Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells. Mol Cancer Res MCR 2008;6(8):1356-64
   PubMed Web of Science ®Google Scholar
• Meinel FG, Mandl-Weber S, Baumann P, et al. The novel, proteasome-independent NF-kappaB inhibitor V1810 induces apoptosis and cell cycle arrest in multiple myeloma and overcomes NF-kappaB-mediated drug resistance. Mol Cancer Ther 2010;9(2):300-10
   PubMed Web of Science ®Google Scholar
• Ramakrishnan V, Kimlinger T, Haug J, et al. TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells. Am J Hematol 2010;85(9):675-86
   PubMed Web of Science ®Google Scholar
• Lin H, Kolosenko I, Björklund A-C, et al. An activated JAK/STAT3 pathway and CD45 expression are associated with sensitivity to Hsp90 inhibitors in multiple myeloma. Exp Cell Res 2013;319(5):600-11
   PubMed Web of Science ®Google Scholar
• Qu Z, Dong H, Xu X, et al. Combined effects of 17-DMAG and TNF on cells through a mechanism related to the NF-kappaB pathway. Diagn Pathol 2013;8:70
   PubMed Web of Science ®Google Scholar
• Zöllinger A, Stühmer T, Chatterjee M, et al. Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma. Blood 2008;112(8):3403-11
   PubMed Web of Science ®Google Scholar
• Asano J, Nakano A, Oda A, et al. The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells. Leukemia 2011;25(7):1182-8
   PubMed Web of Science ®Google Scholar
• Hou C-H, Lin F-L, Hou S-M, Liu J-F. Hyperthermia induces apoptosis through endoplasmic reticulum and reactive oxygen species in human osteosarcoma cells. Int J Mol Sci 2014;15(10):17380-95
   PubMed Web of Science ®Google Scholar
• Li C, Chen S, Yue P, et al. Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation. J Biol Chem 2010;285(21):16096-104
   PubMed Web of Science ®Google Scholar
• Bringhen S, Petrucci MT, Larocca A, et al. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood 2014;124(1):63-9
   PubMed Web of Science ®Google Scholar
• Zoubeidi A, Gleave M. Small heat shock proteins in cancer therapy and prognosis. Int J Biochem Cell Biol 2012;44(10):1646-56
   PubMed Web of Science ®Google Scholar
• Huang W, Ghisletti S, Perissi V, et al. Transcriptional integration of TLR2 and TLR4 signaling at the NCoR derepression checkpoint. Mol Cell 2009;35(1):48-57
   PubMed Web of Science ®Google Scholar
• Grabacka M, Pierzchalska M, Reiss K. Peroxisome proliferator activated receptor α ligands as anticancer drugs targeting mitochondrial metabolism. Curr Pharm Biotechnol 2013;14(3):342-56
   PubMed Web of Science ®Google Scholar
• Peyrl A, Chocholous M, Kieran MW, et al. Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors. Pediatr Blood Cancer 2012;59(3):511-17
   PubMed Web of Science ®Google Scholar
• Kauppinen A, Suuronen T, Ojala J, et al. Antagonistic crosstalk between NF-κB and SIRT1 in the regulation of inflammation and metabolic disorders. Cell Signal 2013;25(10):1939-48
   PubMed Web of Science ®Google Scholar
• Zanardelli M, Micheli L, Cinci L, et al. Oxaliplatin neurotoxicity involves peroxisome alterations. PPARγ agonism as preventive pharmacological approach. PLoS ONE 2014;9(7):e102758
   PubMed Web of Science ®Google Scholar
• Mahmoud MF, El Shazly SM. Pioglitazone protects against cisplatin induced nephrotoxicity in rats and potentiates its anticancer activity against human renal adenocarcinoma cell lines. Food Chem Toxicol 2013;51:114-22
   PubMed Web of Science ®Google Scholar
• Khan S, Lopez-Dee Z, Kumar R, Ling J. Activation of NFkB is a novel mechanism of pro-survival activity of glucocorticoids in breast cancer cells. Cancer Lett 2013;337(1):90-5
   PubMed Web of Science ®Google Scholar
• Toh PPC, Luo S, Menzies FM, et al. Myc inhibition impairs autophagosome formation. Hum Mol Genet 2013;22(25):5237-48
   PubMed Web of Science ®Google Scholar
• He Y, Xu Y, Zhang C, et al. Identification of a lysosomal pathway that modulates glucocorticoid signaling and the inflammatory response. Sci Signal 2011;4(180):ra44
   PubMed Web of Science ®Google Scholar
• Vlahopoulos S, Zoumpourlis VC. JNK: a key modulator of intracellular signaling. Biochem Biokhimiia 2004;69(8):844-54
   PubMed Web of Science ®Google Scholar
• Shanmugasundaram K, Nayak B, Shim E-H, et al. The Oncometabolite Fumarate Promotes Pseudohypoxia Through Noncannonical Activation of NF-κB Signaling. J Biol Chem 2014
   PubMed Web of Science ®Google Scholar
• Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009;69(19):7507-11
   PubMed Web of Science ®Google Scholar
• Laderoute KR, Calaoagan JM, Chao W, et al. 5’-AMP-activated protein kinase (AMPK) supports the growth of aggressive experimental human breast cancer tumors. J Biol Chem 2014;289(33):22850-64
   PubMed Web of Science ®Google Scholar
• Hadad SM, Hardie DG, Appleyard V, Thompson AM. Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle. Clin Transl Oncol 2014;16(8):746-52
   PubMed Web of Science ®Google Scholar
• Cerezo M, Tichet M, Abbe P, et al. Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner. Mol Cancer Ther 2013;12(8):1605-15
   PubMed Web of Science ®Google Scholar
• Malki A, Youssef A. Antidiabetic drug metformin induces apoptosis in human MCF breast cancer via targeting ERK signaling. Oncol Res 2011;19(6):275-85
   PubMed Web of Science ®Google Scholar
• Zordoky BNM, Bark D, Soltys CL, et al. The anti-proliferative effect of metformin in triple-negative MDA-MB-231 breast cancer cells is highly dependent on glucose concentration: implications for cancer therapy and prevention. Biochim Biophys Acta 2014;1840(6):1943-57
   PubMed Web of Science ®Google Scholar
• Zhuang Y, Chan DK, Haugrud AB, Miskimins WK. Mechanisms by which low glucose enhances the cytotoxicity of metformin to cancer cells both in vitro and in vivo. PLoS ONE 2014;9(9):e108444
   PubMed Web of Science ®Google Scholar
• Liu X, Chhipa RR, Pooya S, et al. Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK. Proc Natl Acad Sci U S A 2014;111(4):E435-44
   PubMed Web of Science ®Google Scholar
• Cheng Y, Cai L, Jiang P, et al. SIRT1 inhibition by melatonin exerts antitumor activity in human osteosarcoma cells. Eur J Pharmacol 2013;715(1-3):219-29
   PubMed Web of Science ®Google Scholar
• Lv L, Shen Z, Zhang J, et al. Clinicopathological significance of SIRT1 expression in colorectal adenocarcinoma. Med Oncol Northwood Lond Engl 2014;31(6):965
   PubMed Web of Science ®Google Scholar
• Noguchi A, Kikuchi K, Zheng H, et al. SIRT1 expression is associated with a poor prognosis, whereas DBC1 is associated with favorable outcomes in gastric cancer. Cancer Med 2014. [Epub ahead of print]
   Google Scholar
• Stenzinger A, Endris V, Klauschen F, et al. High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma. BMC Cancer 2013;13:450
   PubMed Web of Science ®Google Scholar
• Tseng R-C, Lee C-C, Hsu H-S, et al. Distinct HIC1-SIRT1-p53 loop deregulation in lung squamous carcinoma and adenocarcinoma patients. Neoplasia N Y N 2009;11(8):763-70
   PubMed Web of Science ®Google Scholar
• Zhang ZY, Hong D, Nam SH, et al. SIRT1 regulates oncogenesis via a mutant p53-dependent pathway in hepatocellular carcinoma. J Hepatol 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Lee C-W, Wong LL-Y, Tse EY-T, et al. AMPK promotes p53 acetylation via phosphorylation and inactivation of SIRT1 in liver cancer cells. Cancer Res 2012;72(17):4394-404
   PubMed Web of Science ®Google Scholar
• Scuto A, Kirschbaum M, Buettner R, et al. SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-κB/STAT3 complex to its promoter in malignant lymphoid cells. Cell Death Dis 2013;4:e635
   PubMed Web of Science ®Google Scholar
• Zhang L, Yang Z, Ma A, et al. Growth arrest and DNA damage 45G down-regulation contributes to Janus kinase/signal transducer and activator of transcription 3 activation and cellular senescence evasion in hepatocellular carcinoma. Hepatol Baltim Md 2014;59(1):178-89
   PubMed Web of Science ®Google Scholar
• Li S, Sun Y, Gao D. Role of the nervous system in cancer metastasis. Oncol. Lett 2013;5(4):1101-11
   PubMed Web of Science ®Google Scholar
• Bottoni U, Clerico R, Paolino G, et al. Appearance of malignant melanoma after a non-cutaneous cancer diagnosis. Ecancermedicalscience 2013;7:315
   Google Scholar
• Neiva KG, Zhang Z, Miyazawa M, et al. Cross talk initiated by endothelial cells enhances migration and inhibits anoikis of squamous cell carcinoma cells through STAT3/Akt/ERK signaling. Neoplasia N Y N 2009;11(6):583-93
   PubMed Web of Science ®Google Scholar
• Umemura A, Park EJ, Taniguchi K, et al. Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition. Cell Metab 2014;20(1):133-44
   PubMed Web of Science ®Google Scholar
• Chang P-C, Wang T-Y, Chang Y-T, et al. Autophagy pathway is required for IL-6 induced neuroendocrine differentiation and chemoresistance of prostate cancer LNCaP cells. PLoS One 2014;9(2):e88556
   PubMed Web of Science ®Google Scholar
• Delk NA, Farach-Carson MC. Interleukin-6: a bone marrow stromal cell paracrine signal that induces neuroendocrine differentiation and modulates autophagy in bone metastatic PCa cells. Autophagy 2012;8(4):650-63
   PubMed Web of Science ®Google Scholar
• Moore EM, Mander AG, Ames D, et al. Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes Care 2013;36(10):2981-7
   PubMed Web of Science ®Google Scholar
• Sethi S, Ali S, Philip PA, Sarkar FH. Clinical advances in molecular biomarkers for cancer diagnosis and therapy. Int J Mol Sci 2013;14(7):14771-84
   PubMed Web of Science ®Google Scholar
• Dorr RT, Shipp NG, Lee KM. Comparison of cytotoxicity in heart cells and tumor cells exposed to DNA intercalating agents in vitro. Anticancer Drugs 1991;2(1):27-33
   PubMed Web of Science ®Google Scholar
• Brana I, Ocana A, Chen EX, et al. A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin. Invest New Drugs 2014;32(6):1269-77
   PubMed Web of Science ®Google Scholar
• Yokoyama Y, Xin B, Shigeto T, Mizunuma H. Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers. J Cancer Res Clin Oncol 2011;137(8):1219-28
   PubMed Web of Science ®Google Scholar
• Dijkgraaf EM, Heusinkveld M, Tummers B, et al. Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer Res 2013;73(8):2480-92
   PubMed Web of Science ®Google Scholar
• Cleator S, Tsimelzon A, Ashworth A, et al. Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance. Breast Cancer Res Treat 2006;95(3):229-33
   PubMed Web of Science ®Google Scholar
• Mozos A, Roué G, López-Guillermo A, et al. The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large b-cell lymphoma. Am J Pathol 2011;179(5):2601-10
   PubMed Web of Science ®Google Scholar
• Bai H, Wei J, Deng C, et al. MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen. Int J Hematol 2013;97(2):223-31
   PubMed Web of Science ®Google Scholar
• Mohammad RM, Al-Katib A, Aboukameel A, et al. Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. Mol Cancer Ther 2003;2(12):1361-8
   PubMed Web of Science ®Google Scholar
• Pirkmajer S, Kulkarni SS, Tom RZ, et al. Methotrexate Promotes Glucose Uptake and Lipid Oxidation in Skeletal Muscle via AMPK Activation. Diabetes 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Vishvakarma NK, Kumar A, Singh V, Singh SM. Hyperglycemia of tumor microenvironment modulates stage-dependent tumor progression and multidrug resistance: implication of cell survival regulatory molecules and altered glucose transport. Mol Carcinog 2013;52(12):932-45
   PubMed Web of Science ®Google Scholar
• Kaehler C, Isensee J, Hucho T, et al. 5-Fluorouracil affects assembly of stress granules based on RNA incorporation. Nucleic Acids Res 2014;42(10):6436-47
   PubMed Web of Science ®Google Scholar
• Xu L, Beckebaum S, Iacob S, et al. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity. J Hepatol 2014;60(3):590-8
   PubMed Web of Science ®Google Scholar
• Valdez BC, Wang G, Murray D, et al. Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications. Exp Hematol 2013;41(8):719-30
   PubMed Web of Science ®Google Scholar
• Amadori S, Stasi R, Martelli AM, et al. Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107). Br J Haematol 2012;156(2):205-12
   PubMed Web of Science ®Google Scholar
• Samuels AL, Heng JY, Beesley AH, Kees UR. Bioenergetic modulation overcomes glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia. Br J Haematol 2014;165(1):57-66
   PubMed Web of Science ®Google Scholar
• Hulleman E, Kazemier KM, Holleman A, et al. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood 2009;113(9):2014-21
   PubMed Web of Science ®Google Scholar
• Lee DH, Qi J, Bradner JE, et al. Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma. Int J Cancer 2014
   Web of Science ®Google Scholar
• Yang X, He G, Gong Y, et al. Mammalian target of rapamycin inhibitor rapamycin enhances anti-leukemia effect of imatinib on Ph+ acute lymphoblastic leukemia cells. Eur J Haematol 2014;92(2):111-20
   PubMed Web of Science ®Google Scholar
• Shi R, Lin J, Guo Y, Gong YP. The MEK1/2 inhibitor U0126 reverses imatinib resistance through down-regulating activation of Lyn/ERK signaling pathway in imatinib-resistant K562R leukemia cells. Pharm 2014;69(5):346-52
   Google Scholar